Paclitaxel

Generic Name: Paclitaxel

Brand Names: Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin

Drug Type: Small Molecule

Chemical Formula: C_₄₇H_₅₁NO_₁₄

CAS Number: 33069-62-4

Unique Ingredient Identifier: P88XT4IS4D

Background: Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.

Indication: Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.

Associated Conditions: Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer

Associated Therapies: -

Clinical Trials

Preoperative Chemotherapy and Bevacizumab in Patients With Stage IB (>4 cm), II, or Select Stage III NSCLC

Phase 2

Terminated

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Carboplatin
Drug: Paclitaxel
Drug: Bevacizumab

First Posted Date: 2009-08-17

Last Posted Date: 2021-12-06

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 4

Registration Number: NCT00960297

Locations: 🇺🇸
Holy Cross Hospital, Fort Lauderdale, Florida, United States
🇺🇸
Tennessee Oncology, Nashville, Tennessee, United States
🇺🇸
Providence Medical Group, Terre Haute, Indiana, United States

and more 3 locations

Paclitaxel, Carboplatin, and Bevacizumab With or Without Cixutumumab in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer

Phase 2

Terminated

Conditions: Recurrent Non-Small Cell Lung Carcinoma
Large Cell Lung Carcinoma
Lung Adenocarcinoma
Stage IV Non-Small Cell Lung Cancer
Bronchioloalveolar Lung Carcinoma

Interventions: Biological: Bevacizumab
Drug: Carboplatin
Biological: Cixutumumab
Drug: Paclitaxel

First Posted Date: 2009-08-10

Last Posted Date: 2018-06-06

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 175

Registration Number: NCT00955305

Locations: 🇺🇸
Longmont United Hospital, Longmont, Colorado, United States
🇺🇸
Smilow Cancer Hospital Care Center at Saint Francis, Hartford, Connecticut, United States
🇺🇸
Hurley Medical Center, Flint, Michigan, United States

and more 161 locations

A Study of MNRP1685A in Combination With Bevacizumab With or Without Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors

Phase 1

Completed

Conditions: Solid Cancers

Interventions: Drug: bevacizumab
Drug: MNRP1685A
Drug: paclitaxel

First Posted Date: 2009-08-07

Last Posted Date: 2017-05-17

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 24

Registration Number: NCT00954642

Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer

Phase 3

Conditions: Stage IA Uterine Sarcoma AJCC v7
Mixed Mesodermal (Mullerian) Tumor
Stage IA Ovarian Cancer AJCC v6 and v7
Stage IB Fallopian Tube Cancer AJCC v6 and v7
Stage IC Ovarian Cancer AJCC v6 and v7
Stage IIA Uterine Sarcoma AJCC v7
Stage IIC Fallopian Tube Cancer AJCC v6 and v7
Stage IIIA Ovarian Cancer AJCC v6 and v7
Stage IIIB Uterine Sarcoma AJCC v7
Stage IV Fallopian Tube Cancer AJCC v6 and v7

Interventions: Drug: Carboplatin
Drug: Ifosfamide
Drug: Paclitaxel
Other: Quality-of-Life Assessment

First Posted Date: 2009-08-07

Last Posted Date: 2021-09-30

Lead Sponsor: GOG Foundation

Target Recruit Count: 637

Registration Number: NCT00954174

Locations: 🇺🇸
Sinai Hospital of Baltimore, Baltimore, Maryland, United States
🇺🇸
Prisma Health Cancer Institute - Easley, Easley, South Carolina, United States
🇺🇸
University of Arizona Cancer Center-North Campus, Tucson, Arizona, United States

and more 532 locations

Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)

Phase 1

Terminated

Conditions: Neoplasms

Interventions: Biological: Robatumumab
Biological: Trastuzumab
Drug: Carboplatin
Drug: Epirubicin
Drug: Everolimus
Drug: Gemcitabine
Biological: Cetuximab
Drug: 5-FU
Drug: Erlotinib
Drug: Paclitaxel
Drug: Cisplatin
Drug: Irinotecan
Drug: Folinic Acid

First Posted Date: 2009-08-07

Last Posted Date: 2018-08-24

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 15

Registration Number: NCT00954512

A Study of Trastuzumab Emtansine, Paclitaxel, and Pertuzumab in Patients With HER2-Positive, Locally Advanced or Metastatic Breast Cancer

Phase 1

Completed

Conditions: Metastatic Breast Cancer

Interventions: Drug: trastuzumab emtansine [Kadcyla]
Drug: pertuzumab [Perjeta]
Drug: paclitaxel

First Posted Date: 2009-08-04

Last Posted Date: 2016-06-24

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 107

Registration Number: NCT00951665

Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Phase 3

Completed

Conditions: Fallopian Tube Serous Adenocarcinoma
Fallopian Tube Clear Cell Adenocarcinoma
Ovarian Clear Cell Adenocarcinoma
Primary Peritoneal Endometrioid Adenocarcinoma
Stage III Ovarian Cancer AJCC v6 and v7
Stage IIIB Ovarian Cancer AJCC v6 and v7
Fallopian Tube Mucinous Adenocarcinoma
Fallopian Tube Undifferentiated Carcinoma
Malignant Ovarian Brenner Tumor
Ovarian Seromucinous Carcinoma

Interventions: Biological: Bevacizumab
Drug: Carboplatin
Drug: Cisplatin
Other: Laboratory Biomarker Analysis
Drug: Paclitaxel
Other: Quality-of-Life Assessment

First Posted Date: 2009-08-04

Last Posted Date: 2021-05-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 1560

Registration Number: NCT00951496

Locations: 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸
Providence Alaska Medical Center, Anchorage, Alaska, United States
🇺🇸
The Hospital of Central Connecticut, New Britain, Connecticut, United States

and more 497 locations

Study of Participants With Advanced Non-Small Cell Lung Cancer

Phase 3

Completed

Conditions: Advanced Non-Small Cell Lung Cancer

Interventions: Drug: Pemetrexed
Drug: Carboplatin
Drug: Paclitaxel
Biological: Bevacizumab

First Posted Date: 2009-07-29

Last Posted Date: 2021-10-29

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 361

Registration Number: NCT00948675

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kennewick, Washington, United States

S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer

Phase 3

Terminated

Conditions: Recurrent Lung Adenocarcinoma
Stage IV Squamous Cell Lung Carcinoma
Stage IV Lung Adenocarcinoma
Recurrent Squamous Cell Lung Carcinoma
Recurrent Large Cell Lung Carcinoma
Stage IV Large Cell Lung Carcinoma

Interventions: Biological: Bevacizumab
Drug: Carboplatin
Other: Laboratory Biomarker Analysis
Biological: Cetuximab
Drug: Paclitaxel

First Posted Date: 2009-07-27

Last Posted Date: 2023-05-23

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 1333

Registration Number: NCT00946712

Locations: 🇺🇸
Riverside Methodist Hospital, Columbus, Ohio, United States
🇺🇸
Columbus CCOP, Columbus, Ohio, United States
🇺🇸
Grant Medical Center, Columbus, Ohio, United States

and more 787 locations

Combination Chemotherapy With CS-1008 to Treat Ovarian Cancer

Phase 2

Completed

Conditions: Ovarian Cancer Stage IV
Ovarian Cancer Stage IIIC

Interventions: Drug: CS-1008
Drug: Paclitaxel
Drug: Carboplatin

First Posted Date: 2009-07-24

Last Posted Date: 2021-04-08

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 24

Registration Number: NCT00945191

Locations: 🇺🇸
University of Oklahoma, Oklahoma City, Oklahoma, United States
🇺🇸
Barnes Jewish Hospital, Saint Louis, Missouri, United States
🇺🇸
Univ. Alabama, Birmingham, Alabama, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy